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ABSTRACT
7,8-Dihydro-8-oxo-2’-deoxyguanosine (8-oxodG) is
a well-known marker of oxidative stress. We report
a mechanistic analysis of several pathways by which
8-oxodG is converted to nucleotide triphosphates
and incorporated into both DNA and RNA. Exposure
of MCF-7 cells to [
14C]8-oxodG combined with
specific inhibitors of several nucleotide salvage
enzymes followed with accelerator mass spectro-
metry provided precise quantitation of the resulting
radiocarbon-labeled species. Concentrations of
exogenously dosed nucleobase in RNA reached
one per 10
6 nucleotides, 5–6-fold higher than the
maximum observed in DNA. Radiocarbon incorpora-
tion into DNA and RNA was abrogated by Immucillin
H, an inhibitor of human purine nucleoside phos-
phorylase (PNP). Inhibition of ribonucleotide reduc-
tase (RR) decreased the radiocarbon content of
the DNA, but not in RNA, indicating an important
role for RR in the formation of 8-oxodG-derived
deoxyribonucleotides. Inhibition of deoxycytidine
kinase had little effect on radiocarbon incorporation
in DNA, which is in contrast to the known ability of
mammalian cells to phosphorylate dG. Our data
indicate that PNP and RR enable nucleotide salvage
of 8-oxodG in MCF-7 cells, a previously unrecog-
nized mechanism that may contribute to mutagen-
esis and carcinogenesis.
INTRODUCTION
Reactive oxygen species (ROS) are important metabolic
by-products that cause cellular damage, particularly to
proteins, lipids and nucleic acids (1,2). ROS are pro-
duced through normal cellular metabolism in most cell
types, primarily through oxidative phosphorylation.
Incomplete transfer of electrons to O2 during oxidative
phosphorylation yields products such as hydrogen per-
oxide, hydroxyl radicals and singlet oxygen species, which
jointly comprise ROS (3). The oxidative modiﬁcations
caused by ROS lead to cell dysfunction and possibly cell
death (4) and are implicated in aging, cancer and other
diseases (5,6).
Much has been published as to how ROS chemically
modify DNA and the nature of these modiﬁcations. It has
been well characterized that when nucleotides are exposed
to ROS, a variety of altered bases are formed (7,8).
Amongst the four normal nucleobases, guanine (Gua) is
the most susceptible to oxidation due to its low oxidation
potential (9–11). The most abundant oxidized nucleobase
found in DNA is 7,8-dihydro-8-oxoguanine (8-oxoGua,
Figure 1A) (12). When present in DNA, 8-oxoGua can
pair with both cytosine and adenine leading to G!T
transversion mutations during replication and DNA
repair. Likewise, 8-oxodGTP can mispair with adenine
nucleotides to cause A!C transversion point mutations.
The formation of 8-oxoGua in DNA has been shown to
occur via two pathways: (i) through direct oxidation of
Gua in DNA or (ii) indirectly via oxidation of dGTP in
the nucleotide pool to 8-oxodGTP, followed by incor-
poration of 8-oxodGTP into the DNA by DNA poly-
merase(s) (1,13). A third pathway, metabolism of the
20-deoxynucleoside 7,8-dihydro-8-oxo-20-deoxyguanosine
(8-oxodG) to 8-oxodGTP has only recently been reported
(14,15), but with incomplete mechanistic detail. The
nucleotide pool containing 8-oxodG may be modulated
by extracellular sources. It is known that the repair
products from other cells, cell turnover and the diet of
the individual contribute to the 8-oxodG load as well.
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plasma (16,17) and cerebrospinal ﬂuid (18).
8-OxoGua is premutagenic and the cell employs a
number of repair pathways to limit the presence of this
species in DNA. Cells primarily use base excision repair
(BER) to remove oxidized purines (19). In humans, the
hOGG1 glycosylase removes 8-oxoGua from DNA when
incorporated opposite cytidine (20,21). The Escherichia
coli (E. coli) MutY homolog, MYH, removes the
misincorporated adenine when opposite 8-oxoGua in
DNA (19,22). In the nucleotide pool, the E. coli
MutT homolog, hMTH1, hydrolyzes 8-oxodGTP to
8-oxodGMP to prevent 8-oxoGua incorporation into
DNA (23,24). More recently, evidence has emerged that
mismatch repair is synergistic with both hMTH1 and
hOGG1 in lowering mutation frequencies due to 8-
oxodG-derived species (22,24,25).
In contrast to 8-oxoGua in DNA, little information is
available on the mutagenic potential and cellular
responses to the 8-oxodG. Based upon known nucleotide
salvage pathways (26,27), we hypothesized that 8-oxodG
(Figure 1A) can be metabolized in two diﬀerent ways.
Direct mono-, di- and triphosphorylation of the nucleo-
side would result in formation of 8-oxodGTP, a substrate
for DNA replication. Alternatively, processing of
8-oxoGua (free nucleobase) can form the nucleotide
triphosphates 8-oxoGTP and 8-oxodGTP for both RNA
and DNA synthesis after removal of the 20-deoxyribose
moiety. Both pathways reﬂect the known metabolism of
the canonical 20-deoxynucleoside dG (28) (Figure 1B).
Brieﬂy, as shown in Figure 1B, in the cytoplasm of
human cells, dG undergoes phosphorolysis to the free
nucleobase Gua and 20-deoxyribose-10-phosphate by
purine nucleoside phosphorylase (PNP). The resulting
free base is then phosphoribosylated by hypoxanthine–
guanine phosphoribosyltransferase (HGPRT) (16). Two
additional phosphorylation steps result in the formation
of GTP, which serves as a substrate for RNA polymerase-
dependent incorporation into RNA. Alternatively,
deoxycytidine kinase (dCK) in the cytoplasm, or deoxy-
guanosine kinase (dGK) in mitochondria, phosphorylates
dG to form dGMP. The monophosphate is subsequently
phosphorylated to form dGTP, a substrate for DNA
polymerase-dependent incorporation into DNA. These
two major salvage pathways are connected by ribonucleo-
tide diphosphate reductase (RR), which forms dGDP
from GDP by replacement of the 20-OH with a hydrogen
atom. Upon subsequent phosphorylation, the resulting
dGTP serves as a nucleotide for DNA synthesis.
In the present article, we report evidence that 8-oxodG
is a substrate for nucleotide salvage. We investigated
whether cells dosed with extracellular [
14C]8-oxodG are
able to employ either the dCK- or the PNP-dependent
pathway (via RR) by quantitation of the radiocarbon on
the nucleobase portion of the molecule present in the
nucleotide pool and nucleic acids of MCF-7 cells under a
variety of conditions. Using accelerator mass spectro-
metry (AMS), we measured the radiocarbon content
in DNA and RNA of cells dosed with [
14C]8-oxodG
in concert with inhibitors of several nucleotide salvage
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Figure 1. (A) Structures and abbreviations of guanine (Gua), deoxyguanosine (dG), 8-oxoguanine (8-oxoGua), 8-oxodeoxyguanosine (8-oxodG) and
8-oxoguanosine (8-oxoG), respectively. The asterisk on 8-oxodG indicates the
14C label. (B) Nucleotide salvage pathways for dG and inhibitors that
can be used to elucidate which are the predominant metabolic pathways. In the cytoplasm, dG undergoes phosphorolysis to the free nucleobase Gua
and 20-deoxyribose-10-phosphate by human purine nucleoside phosphorylase (PNP, top left). The resulting free base is then phosphoribosylated by
hypoxanthine-guanine phosphoribosyltransferase (HGPRT). Two additional phosphorylation steps result in formation of GTP, which serves as a
substrate for RNA polymerase-dependent incorporation into RNA. Alternatively, deoxycytidine kinase (dCK, bottom left) in the nucleus or
deoxyguanosine kinase (dGK) in mitochondria use dG as a substrate to form dGMP. This in turn is phosphorylated twice to form dGTP, a substrate
for DNA polymerase-dependent incorporation into DNA. These two major salvage pathways are connected by ribonucleotide diphosphate reductase
(RR), which forms dGDP from GDP. Upon subsequent phosphorylation, the resulting dGTP serves as a nucleotide for DNA synthesis. IH, dC and
HU stand for Immucillin H, deoxycytidine and hydroxyurea, respectively.
Nucleic Acids Research,2008, Vol. 36,No. 1 229enzymes. AMS is a well-established technology for radio-
carbon dating and is now in development for tracing
14C-labeled compounds in biological systems, aﬀording
sub-attomole
14C per milligram of total carbon sensitivity
with a few percent precision (15,29,30). This sensitivity
allowed us to observe 8-oxodG metabolism in cells
without using large concentrations of 8-oxodG that may
have rendered artifactual data due to pathway saturation.
Our combined results support the conclusion that the
PNP-dependent mechanism is the major pathway by
which 8-oxodG is incorporated both into DNA and
RNA of MCF-7 breast cancer cells.
MATERIALS AND METHODS
Cellculture andincubation with [
14C]8-oxodG
MCF-7 human breast cancer cells originally obtained
from ATCC were maintained in DMEM-F12 (Invitrogen/
Gibco, Carlsbad, CA, USA) media supplemented with
10% fetal bovine serum (FBS) (Invitrogen/Gibco) and
10mg/ml insulin (Invitrogen/Gibco). A total of 5 10
5
cells were plated and grown for 24h in a 10-cm dish before
dosing. Cells were incubated with radiocarbon-labeled
8-oxodG for time periods indicated in ﬁgure legends, prior
to harvest (10.8 pmol per plate with a speciﬁc activity
of 12.5mCi/mmol, measured as 300d.p.m./ml by liquid
scintillation counter). [
14C]8-OxodG synthesis was per-
formed as described (14).
DNA and RNA extraction from MCF-7 cells
At harvest, the media was removed and the cells were
washed with phosphate-buﬀered saline (PBS, Invitrogen/
Gibco), removed from the plate with trypsin (Invitrogen/
Gibco) and washed by centrifugation in PBS. DNA and
RNA were harvested using Trizol (Invitrogen, Carlsbad,
CA, USA). To remove RNA contamination, the DNA
was treated with RNase and puriﬁed using a DNeasy
reverse-phase cartridge (Qiagen, Valencia, CA, USA).
Likewise, for RNA samples, contaminating DNA was
removed using an RNeasy kit from Qiagen and the on-
column DNase kit was employed. The [
14C]8-oxodG was
 99% chemically and radiochemically pure; the DNA
isolation method was previously reported to not cause
spurious oxidation of [
14C]8-oxoG in DNA (15). In the
previously reported work, the DNA was digested to
deoxyribonucleosides and there were negligible ribonu-
cleotides as assayed by HPLC. Furthermore, exposure of
the puriﬁed DNA to the DNA glycosylase, Fpg, which
excises 8-oxodG from duplex DNA, resulted in loss of
>95% of the radiocarbon from the DNA, indicating little
or no contamination from [
14C]RNA. AMS samples were
prepared in triplicate from puriﬁed DNA or RNA (1mg)
after addition of carrier carbon in the form of 1ml
of tributyrin (ICN Chemical Co.). AMS samples were
analyzed as described (15).
Inhibitorstudies
Cells were dosed for inhibitor studies in combination
with [
14C]8-oxodG as described earlier, except with a
pre-treatment with the inhibitor 6h prior to [
14C]8-oxodG
dosing (30h total inhibition). Inhibitor doses were chosen
such that the maximum dose displayed no eﬀect on cell
proliferation and cell death compared to a no-dose
control. Immucillin H was prepared as described (31,32)
and was used in concentrations increasing 10-fold from
10 nM to 10 mM. Deoxycytidine (dC, Sigma Chemical
Co.) was used at 20 mM, 100 mM and 1mM concentra-
tions, and when dosed in combination with [
14C]8-oxodG
and 100 nM Immucillin H, 100mM dC was used.
Hydroxyurea (HU, Sigma Chemical Co.) was used at
100mM, 250mM and 500mM.
HPLC separation following cell lysis
After 2 days of incubation with [
14C]8-oxodG, the media
was removed and the cells were washed three times with
PBS. Cells were removed from the plate with trypsin,
washed by centrifugation in PBS and lyzed with 1ml of
Lysis Solution from the DNA Extractor WB Kit (Wako
Pure Chemical Industries, Ltd.). The resulting lysate was
ﬁltered using a Millipore Ultrafree-MC centrifugal ﬁlter.
The lysate (100ml) was analyzed by reverse-phase (RP)
and anion-exchange (AE) HPLC–AMS using published
protocols (15,33–35). Radiocarbon content and elution
times were calibrated with authentic mono-, di- and
triphosphorylated 20-deoxyribosyl and ribosyl derivatives
of 8-oxoGua. The standards were purchased from Trilink
BioTechnologies Inc. (San Diego, CA, USA), except for
8-oxodGMP, which was synthesized according to the
literature (15,36).
Proliferation assayand cell deathassay
Cells were plated and incubated for 24h before treatment.
Samples were dosed in triplicate for a total of 30h with
each speciﬁc inhibitor. For cell death, cells were plated
in 60-cm plates and harvested by trypsination. At least
200 cells per plate were counted using the trypan blue
exclusion assay. The mean for the replicates is represented
and standard error is shown.
Cell proliferation was measured by reduction of
the yellow tetrazolium 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma, St. Louis,
MO, USA) by metabolically active cells, following
quantitation of the resulting intracellular purple forma-
zan. Cells were plated into a 96-well plate at  1000 cells/
well. After 24h incubation, cells were dosed with indicated
concentrations of Immucillin H, dC and HU. After
additional 24-h incubation, 100ml of 12.1mM each
compound was added per well and incubated for 3h at
378C. The MTT was removed and 100ml of 100% DMSO
was added to each well and the plate was read at 550nm.
Statistical analysis
For each experiment, the calculated mean of a represen-
tative example is shown. Each point was conducted
in triplicate and standard error is indicated. For the
Student’s t-test, Microsoft Excel was used to calculate one
tail and two tail probabilities and the results were
considered signiﬁcant if p<0.05.
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Incorporation ofradiocarbon from [
14C]8-oxodG
into DNA andRNA
MCF-7 cells grown in the presence of radiolabeled
8-oxodG for up to 5 days were harvested and analyzed
by AMS for radiocarbon content in DNA and RNA
(Figure 2A). The maximal incorporation of 8-oxoGua
into DNA after 24h was 3.4 0.2fmol per microgram of
DNA compared to 13.0 0.2fmol per microgram of
RNA. After washing the cells and replenishing with
radiocarbon-free media, the radiocarbon content in DNA
decreased by roughly half, each day during a 3-day time
course. This reduction is likely due to DNA repair and
dilution of signal due to cell division, approximating the
doubling time of MCF-7 cells common in our laboratory.
After 3 days of growth, the average daily reduction was
only 17% probably due to the slowed growth as the cells
reached conﬂuence. Average radiocarbon content in RNA
decreased by 35% each day.
Cell lysates from MCF-7 cells grown in the presence of
radiolabeled 8-oxodG for 2 days were syringe-ﬁltered in
preparation for HPLC–AMS. The samples were injected
onto a reverse phase (RP) HPLC system in order to
characterize the formation of 8-oxodG metabolic products
in the nucleotide pool (34,35). Fractions collected at 1-min
intervals were analyzed by AMS for radiocarbon content.
The elution times of fractions containing elevated radio-
carbon concentrations were compared to those of
authentic standards of mono-, di- and triphosphorylated
20-deoxyribosyl and ribosyl derivatives of 8-oxoGua, for
which the retention times were 9.1, 6.1, 4.7, 3.3, 2.9 and
2.8min, respectively. The fractions containing elevated
radiocarbon levels corresponded to retention times con-
sistent with these authentic standards (Figure 2B).
Importantly, we also found elevated radiocarbon levels
that co-eluted with unmodiﬁed 8-oxodG (retention time of
22.6min).
In addition, the samples were also injected onto an AE
HPLC column in order to alternatively conﬁrm the
formation of 8-oxodG metabolism products in the
nucleotide pool (Figure 2C). Fractions collected at 1-min
intervals were analyzed by AMS for radiocarbon content,
as described earlier. The elution times of fractions
containing elevated radiocarbon concentrations were
comparable to those of authentic standards of 8-oxodG,
mono-, di- and triphosphorylated 20-deoxyribosyl and
ribosyl 8-oxoGua, of which the retention times are 4.5,
7.4, 9.7, 12.4, 7.7, 10.6 and 13.1min, respectively. The
fraction co-eluting with 8-oxodG shown in panel 2B has
relatively low radiocarbon content, whereas the content of
radiocarbon in the component co-eluting with 8-oxodG
shown in panel 2C dominates the content of radioactivity.
A signiﬁcant amount of radiocarbon was found for
fractions eluting between 8-oxoGMP and 8-oxodGTP.
This raises the possibility of the presence of signiﬁcant
amount of unknown radiocarbon-containing components
present in the cell lysate. These diﬀerences may, in part, be
due to speciﬁc characteristics of the HPLC method, such
as elution of radiocarbon with the solvent front, as is
likely in panel 2C. Also, we did not use a standard of
8-oxoGua, since there is an issue of poor solubility in the
buﬀers used. Since AMS–HPLC relies on coelution with
standards, the method is limited in capability for
producing new molecular information. However, it is
clear that 8-oxodG is metabolized in these cells.
To test the PNP involvement in 8-oxodG metabolism
directly, we used Immucillin H, a PNP-speciﬁc inhibitor,
in cell culture experiments. Immucillin H is a transition-
state analog inhibitor that is currently in Phase II trials as
an anti-leukemia agent (32,37). Cells were pre-treated with
Immucillin H for 6h and then dosed with [
14C]8-oxodG.
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Figure 2. 8-OxodG incorporates into DNA and RNA. (A) AMS data
from a 5-day time course after exposure to [
14C]8-oxodG in MCF-7
cells. (DNA in white, RNA in gray) (B) Reverse-phase HPLC–AMS
and (C) anion-exchange HPLC–AMS data from cell lysates after
a 2-day exposure to [
14C]8-oxodG in MCF-7 cells. HPLC trace
represented on right axis, AMS data represented as a bar graph for
each HPLC fraction, with axis on the left.
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14C content in both DNA and RNA was
measured by AMS in triplicate samples. We found 1.5
( 0.2) fmol
14C per microgram of DNA and 8.9 ( 0.4)
fmol
14C per microgram of RNA when the cells were
dosed with [
14C]8-oxodG in the absence of inhibitor
(Figure 3A). At 10 nM Immucillin H, there was no
signiﬁcant inhibition (Student’s T-test p<0.05) of [
14C]8-
oxodG incorporation in DNA and a relatively small, but
signiﬁcant inhibition of incorporation into RNA (34%).
In contrast, 100 nM Immucillin H resulted in nearly
complete inhibition of incorporation into both DNA and
RNA (86% and 74% average reduction, respectively). At
this dose, the reduction of 8-oxodG incorporation into
DNA was not statistically signiﬁcant when compared to
micromolar concentrations of Immucillin H. The 1mM
dose, but not the 10mM dose, resulted in a signiﬁcant
reduction of incorporation into RNA compared to the
100nM concentration, although overall the magnitude of
the change at any dose was small. Combined, these data
suggest that PNP is a primary nucleotide salvage pathway
mediator of 8-oxodG metabolism.
We also examined the contribution of direct phosphor-
ylation of 8-oxodG via the dCK pathway. dC is a known
inhibitor of dCK and operates through competition
between dCTP and dC to act as a substrate. Cells were
pre-treated with increasing concentrations of dC for 6h
prior to the addition of [
14C]8-oxodG (Figure 3B).
Incorporation of
14C 24h after 8-oxodG dosing was
examined in both DNA and RNA using AMS. We
observed no signiﬁcant reduction of radiocarbon incor-
poration in both DNA and RNA compared to untreated
cells regardless of the concentration of dC used. These
data support that dCK does not contribute to 8-oxodG
incorporation from the nucleotide pool into nucleic acids.
Since there was a residual amount of incorporation
observed even in the presence of high concentrations of
Immucillin H and dC, it was possible that the inhibition of
PNP caused shunting of purine salvage through the dCK
pathway. If this is true, then inhibition of PNP and dCK
should result in a complete depletion of incorporation
of
14C into DNA or RNA. When we performed this
experiment at the highest concentrations of Immucillin H
and dC used for the previous experiments there was no
further reduction in the
14C incorporation (Figure 3B, far
right). This result suggests either incomplete inhibition
of the enzymes or the use of another pathway that makes
a minor contribution to 8-oxodG metabolism and
incorporation into DNA and RNA compared to the
PNP-mediated nucleotide salvage.
Assuming that PNP is the primary participant in the
nucleotide salvage of 8-oxodG, the incorporation of
[
14C]8-oxodG into DNA would depend on the activity
of RR to form the 8-oxodGTP derivative required by
DNA polymerase. In this case, inhibition of RR should
result in
14C incorporation into RNA but not into DNA.
To test this possibility, we used HU to inhibit RR. HU is a
radical scavenger that inactivates RR by directly reducing
the tyrosyl radical of an RR subunit during catalysis.
Unlike many other RR inhibitors, it does not require
activation by dCK (38,39).
We incubated MCF-7 cells with HU for 12h and then
added [
14C]8-oxodG for 24h before harvesting the DNA
and the RNA (Figure 4).
14C incorporation into DNA was
reduced by an average of 21% and 42% at 250 and
500mM, respectively. This inhibition was statistically
signiﬁcant compared to the untreated control (p<0.05),
whereas no change was observed in the incorporation of
[
14C]8-oxodG into RNA. These observations are con-
sistent with 8-oxoGua forming from 8-oxodG via PNP-
mediated N-glycosidic bond cleavage, with subsequent
phosphoribosylation and conversion to 8-oxoGTP prior
to incorporation into RNA. Our data indicate that the
primary mechanism of 8-oxodG metabolism is through
the PNP and RR enzymes, which supports our observa-
tion that [
14C]8-oxodG can be incorporated into both
RNA and DNA.
An alternative possibility is that the reduced incorpora-
tion observed was due to the toxicity of the inhibitors,
or modulation of proliferation rates. Immucillin H is
potentially toxic because dG is shunted through dCK
possibly causing accumulation of enough dGTP to block
DNA synthesis (32).
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Figure 3. 8-OxodG is a substrate for PNP, but not dCK. MCF-7 cells were dosed with [
14C]8-oxodG in combination with increasing concentrations
of (A) Immucillin H (IH) or (B) dC where indicated. RNA (gray) and DNA (white) were harvested and puriﬁed from the cells 24h after dosing.
One microgram of DNA or RNA was analyzed by AMS.
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the inhibitors for 30h (6h of pre-treatment plus 24h of
8-oxodG exposure) at the highest concentrations used
in the 8-oxodG metabolism studies. Cells were dosed,
harvested and assessed for cell death using the trypan blue
exclusion assay, where dead cells are counted by virtue
of their ability to absorb the dye. We found that the
treatments were not substantially toxic compared to the
untreated control (Figure 5A).
Additionally, we examined the eﬀects of these inhibitors
on cell proliferation (Figure 5B) using the MTT assay,
where only living cells are capable of carrying out the
enzymatic reaction necessary for the colorimetric change.
There was no diﬀerence in proliferation in the dosed cells
compared to controls at all inhibitor concentrations.
Therefore, we could conclude that the reduced incorpora-
tion of [
14C]8-oxodG in the presence of Immucillin H or
HU was due to enzyme-speciﬁc inhibition, and not due to
toxicity or growth arrest artifacts.
DISCUSSION
Given the high levels of 8-oxodG found excreted from
cancer patients (40), and its prominent accumulation as an
oxidized nucleobase, 8-oxodG has been regarded as a
biomarker of disease. There are many reports examining
the role that the nucleotide pool plays in contributing to
the mutagenic consequences of 8-oxodG (7,8), but
measurement of the eﬀects of oxidative stress in a cellular
environment is often hampered by poor measurement
sensitivity and precision. Our present data make use of the
highly sensitive AMS technology to follow radiocarbon-
labeled 8-oxodG as it is metabolized by human breast
cancer cells. Experiments from multiple laboratories
conducted in parallel by ESCODD reported that
8-oxodG levels are within 0.3 and 4.2 per 10
6 guanines
in human lymphocyte DNA (41). Our results fall within
these levels. Furthermore, Park and coworkers (16) found
concentrations of 69 15 fmol/ml of 8-oxodG in human
plasma. Our supplemental concentration of 108 fmol/ml
of 8-oxodG is roughly equivalent to this, thus making our
dosage physiologically relevant to the study.
There are conﬂicting reports as to the ability of diﬀerent
cell types to incorporate exogenous 8-oxodG into nucleic
acids and by which mechanisms. For example, there is
evidence that neither dCK nor dGK is able to metabolize
8-oxodG (42,43). There is also evidence that [
14C]8-oxodG
is not a substrate for the PNP enzyme, nor for DNA
polymerases (42). Importantly, however, these published
data were gathered using puriﬁed enzymes and cell
extracts that may lack cofactors or cellular integrity
required for full utilization of the proposed pathways for
8-oxodG metabolism. In contrast, our data were obtained
in intact cells containing all known or unknown cofactors
required for nucleotide salvage cells, using physiologically
relevant concentrations of 8-oxodG. Our results are
facilitated by the use of AMS. AMS is speciﬁc only to
the labeled compound in any biological or chemical
medium without prior speciation or introduction of
molecular modiﬁcations or internal standards.
The observed incorporation of 8-oxodG into DNA in
MCF-7 cells seems to contrast with Kim and Chung (43)
who found incorporation of [
3H]dG but not [
3H]8-oxodG
in similar experiments using scintillation counting.
However, the mechanistic analysis presented herein
provides an explanation, since the tritium label from
Kim et al. was located on the 20-deoxyribose ring.
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Figure 4. 8-OxoGDP is a substrate for RR. MCF-7 cells were
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nucleobase, which would preclude incorporation of the
tritium label into DNA and RNA. In our present article,
8-oxodG was labeled with
14C on the nucleobase, allowing
tracking of its metabolism in the absence of the sugar ring,
which allowed elucidation of the contribution of the PNP-
mediated salvage pathway. The reported elevated incor-
poration of [
3H]dG into DNA compared to [
3H]8-oxodG
supports more facile direct phosphorylation of dG,
compared to 8-oxodG, which is independent of PNP.
Our experiments clearly demonstrate that 8-oxodG
from the nucleotide pool is incorporated both into the
DNA and the RNA (Figure 2).
14C content in RNA was
measured to be 5–6 times higher than in DNA, which may
be explained by the constitutive transcription of RNA or
the larger pool size of ribonucleotides (42). The radio-
carbon concentrations that we observed for this work are
higher than previously reported (15,44), possibly due to
optimized media composition with respect to supplemen-
tal insulin. While there could be trace amounts of RNA
in the harvested DNA, our samples were digested with a
protocol that was optimized against residual RNA (15).
We attribute these higher levels of incorporation to the
higher proliferation rate of MCF-7 cells in the presence of
supplemental insulin, which resulted from optimization of
the cell culture conditions. The levels of 8-oxodG reported
here are approximately 1 molecule per 10
6 nucleotides,
which is equivalent to the background level of 8-oxodG
in many cell types (45). Our results remain consistent
with the levels of 8-oxodG in the cells as predicted by
ESCODD by labs using HPLC with electrochemical
detection (46).
The RP HPLC–AMS data support that 8-oxodG in the
nucleotide pool is metabolized to the corresponding
ribosyl and 20-deoxyribosyl triphosphorylated species
that serve as substrates for both RNA and DNA
polymerases (Figure 2B), which is consistent with the
same experiment performed with AE HPLC–AMS
(Figure 2C). Since these experiments simply show co-
elution of 8-oxodG metabolites with authentic standards,
these data alone do not prove the conversion of 8-oxodG
to triphosphorylated 20-deoxyribosyl and ribosyl deriva-
tives of 8-oxoGua. It would be desirable to have better
separation of the HPLC peaks in order to allow
quantitation of [
14C]8-oxodG metabolites, particularly
with exposure of cells to Immucillin H. The data support
that the radiolabeled compound is metabolized to several
species whose retention times are consistent with nucleo-
sides and nucleotides.
The HPLC–AMS data combined with the observation
that [
14C]8-oxodG incorporates into both DNA and RNA
strongly support the interpretation that, free 8-oxodG
is converted to triphosphorylated derivatives prior to
incorporation into DNA and RNA. The RP- and AE-
HPLC–AMS data are consistent with metabolism of
8-oxodG to several phosphorylated species that are
expected to be existent based upon the PNP- and RR-
mediated nucleotide salvage of dG.
Our results further demonstrate that the PNP enzyme is
important to the incorporation of 8-oxoG into RNA and
that RR is used to form the deoxyribonucleotides
necessary for incorporation into DNA (Figure 6). At
this point, the perturbation of other pathways relevant to
nucleotide salvage by Immucillin H cannot be ruled out,
but there are currently no reports of other enzymes for
which Immucillin H is a substrate. However, Immucillin H
is now in phase IIb clinical trials and has had extensive
testing in cells, animals and humans. To date, no
additional eﬀect other than PNP inhibition has been
attributed to the inhibitor. For example, administration
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234 Nucleic Acids Research, 2008, Vol. 36, No. 1of Immucillin-H causes a change in blood patterns in
humans that are the same as those found in humans with
a genetic deletion in PNP (47).
Each inhibitor experiment was carried out at least three
times with triplicate plates of cells for each inhibitor
concentration sampled. AMS measurements were taken
repeatedly on each sample until a threshold number of
counts were recorded. The variation in the data is certainly
due to diﬀerences in the cell culture experiments. We do
not understand the small but statistically signiﬁcant
increase in the DNA radiocarbon from the 100mM dose
of HU shown in Figure 4. The minimal role for dCK in
8-oxodG salvage is consistent with previous publications
that argue against a step-wise phosphorylation mechanism
for 8-oxodG incorporation (42,43). Given that the
inhibition of dCK and PNP concurrently did not reduce
incorporation to zero, an alternative pathway may
function in a minimal capacity.
This work re-identiﬁes 8-oxoGua as an important and
potentially mutagenic substrate for incorporation into
DNA. Our results ultimately imply that 8-oxoGua
generated by the BER process may be cycled back for
incorporation into DNA. Furthermore, since 8-oxodG is
ﬁrst converted to 8-oxoGua, extracellular 8-oxodG likely
contributes more to mutagenesis than previously recog-
nized. Given the metabolism of 8-oxoGua to a substrate
that can be incorporated into DNA, the role of the Nudix-
hydrolases becomes much more central to prevent
mutations. In light of these new data, the contribution
of the nucleotide pool with respect to oxidation of DNA-
incorporated modiﬁed guanines becomes signiﬁcant and
needs to be assessed further (48). Future work will
examine the cell-speciﬁc nature of these results, since
there are several reports that support the possibility that
8-oxoG levels DNA may be enhanced in cancer cells (49).
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